CPRX Earnings Date & History
Catalyst Pharmaceuticals Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:36 PM ET
Catalyst Pharmaceuticals Inc
Biotechnology
- Next earnings date
- Tuesday, November 3, 2026
- Reporting session
- Time TBD
- EPS estimate
- $0.51
- Revenue estimate
- $164.8M
CPRX earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Monday, May 11, 2026 | Q1 2026 | $0.47 | $0.50 | +7.5% | $149.4M |
| Wednesday, February 25, 2026 | Q4 2025 | $0.34 | $0.41 | +19.6% | $152.6M |
| Wednesday, November 5, 2025 | Q3 2025 | $0.34 | $0.42 | +24.0% | $148.4M |
| Wednesday, August 6, 2025 | Q2 2025 | $0.39 | $0.41 | +4.1% | $146.6M |
What the market is watching in CPRX's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next CPRX earnings date?
- Catalyst Pharmaceuticals Inc is scheduled to report on Tuesday, November 3, 2026 (Time TBD). Dates can change until the company confirms them.
- Does CPRX report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for CPRX?
- Consensus EPS for the upcoming quarter is $0.51, on revenue of $164.8M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
CPRX earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.